Takeda Pharmaceutical (TAK) said Tuesday the European Commission approved Adcetris in combination with a chemotherapy regimen to treat patients with stage 2b, 3 and 4 Hodgkin lymphoma.
The Commission's approval follows a recommendation from the Committee for Medicinal Products for Human Use on April 25, according to a statement.
The approval is based on the phase 3 HD21 trial, which achieved its co-primary safety and efficacy endpoints, the company said.
It added that the development marks the second approval for the drug regimen for the treatment of Hodgkin lymphoma.
Price: 14.99, Change: -0.09, Percent Change: -0.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.